Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid

Cole, Connor; Borradori, Luca; Amber, Kyle T.

doi:10.3390/antib11030044

Cited by 5 publications

(3 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over 90% of BP patients have IgG autoantibodies that target the extracellular membrane-proximal portion (NC16A domain) of BP180. However, circulating anti-BP230 IgG and IgE autoantibodies are seen in up to 80% and 68%, respectively [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer

Sabaté Ortega,

Fort Culillas,

Escoda Garcia

et al. 2023

Current Oncology

View full text Add to dashboard Cite

Cutaneous immune-related adverse events (cirAEs) are the most common side effects of immune checkpoint inhibitor (ICI) therapy (30–50% for all grades). The vast majority of them are low or mild and can be treated without ICI interruption. Autoimmune blistering disorders, such as immune-mediated bullous pemphigoid (IBP), are rare (<1%) but potentially serious conditions that must be early detected. The onset generally occurs within the first months of the treatment, and it appears to be more common with antiprogrammed death-1 or antiprogrammed ligand 1 (anti-PD1/PDL1) than with anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4). We present a case of a three-day severe IBP onset after receiving the first cycle of atezolizumab. This exceptional early presentation could suggest the presence of some predisposing condition and demonstrates the need to better understand predictive toxicity-related biomarkers in candidate patients for immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer

Sabaté Ortega,

Fort Culillas,

Escoda Garcia

et al. 2023

Current Oncology

View full text Add to dashboard Cite

show abstract

“…The presence of circulating and tissue-bound IgG autoantibodies directed against BP180 and BP230 [ 41 ].…”

Section: Figurementioning

confidence: 99%

Arising Concerns of Atypical Manifestations in Patients with Hand, Foot, and Mouth Disease

et al. 2023

View full text Add to dashboard Cite

Hand, foot, and mouth disease (HFMD) is a mild exanthematous, febrile disease, but it also remains a threat to global public health. HFMD is characterized by a brief febrile illness in children and with a typical skin rash of the hand and foot, with or without mouth ulcers. However, the morphology and distribution of vesicles, as well as accompanying symptoms, are varied among atypical HFMD. An upsurge in atypical presentations of HFMD caused by Coxsackievirus A6 (CVA6), including Gianotti–Crosti-like eruptions, eczema coxsackium, petechial/purpuric eruption, and vesiculobullous exanthema, can be difficult to diagnose clinically as it may mimic other severe skin diseases, such as eczema herpeticum, varicella, disseminated zoster, and erythema multiforme major. The recognition of the distinguishing features of atypical HFMD is vital for an accurate and timely diagnosis, as is initiating appropriate laboratory evaluation and supportive care. Clinicians must identify the wide range of cutaneous and mucosal alterations caused by atypical HFMD. A systemic, high-quality overview of atypical HFMD is needed for advances in better strategies for clinical diagnosis and treatment. Hence, this review is aimed at summarizing the available data on clinical investigations and differential diagnostics to provide a scientific guide for the timely diagnosis of HFMD for preventing serious complications.

show abstract

“…Similar to BP, inflammation is the major trigger of the early phases of the atherosclerotic process and inflammatory cytokines are associated with a higher risk for developing cardiovascular diseases (75). Next to BP-230-a and BP-230-e, a third isoform named BP-230-b is known (76). This isoform is mainly expressed in the myocardium and skeletal muscle of mice (77).…”

Section: Cardiovascular and Metabolic Diseasesmentioning

confidence: 99%

Comorbidity in bullous pemphigoid: up-date and clinical implications

Huttelmaier,

Benoit,

Goebeler

2023

Front. Immunol.

View full text Add to dashboard Cite

Bullous pemphigoid is the most common autoimmune blistering disease in industrialized countries and particularly affects the elderly. In this patient population, comorbid diseases are frequent and may complicate management and treatment of bullous pemphigoid. A better understanding why distinct diseases are more frequent in bullous pemphigoid patients may lead to new pathophysiological insights and - as a consequence - result in better patient care. The association of bullous pemphigoid with neurological and psychiatric diseases is well known and confirmed by several case-control studies. Association with further diseases such as malignancy and metabolic diseases are still discussed controversially. In recent years new relationships between bullous pemphigoid and autoimmune as well as inflammatory skin diseases have been reported. This review provides a systematic overview on studies addressing comorbidity in bullous pemphigoid patients. Increasing the awareness of both, common and rare comorbid diseases, may enable clinicians to optimize patient support and individualized treatment of bullous pemphigoid.

show abstract

Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid

Cited by 5 publications

References 86 publications

Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer

Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer

Arising Concerns of Atypical Manifestations in Patients with Hand, Foot, and Mouth Disease

Comorbidity in bullous pemphigoid: up-date and clinical implications

Contact Info

Product

Resources

About